GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, will report its first quarter 2025 financial results on May 1, 2025, after U.S. market close. The company will host a conference call at 4:30 p.m. ET to provide a comprehensive corporate update and discuss its quarterly financial performance.
The company's current research focuses on multiple critical areas, including a next-generation COVID-19 vaccine, GEO-CM04S1, which is undergoing three Phase 2 clinical trials. These trials are exploring the vaccine's potential for immunocompromised patients, as a booster for chronic lymphocytic leukemia patients, and as a more robust booster for individuals previously vaccinated with mRNA vaccines.
In addition to its infectious disease research, GeoVax is advancing oncological treatments. The company recently completed a Phase 1/2 clinical trial for Gedeptin®, a novel oncolytic solid tumor gene-directed therapy targeting advanced head and neck cancers. The firm is also developing GEO-MVA, a vaccine aimed at combating Mpox and smallpox.
The upcoming conference call represents an important opportunity for investors and stakeholders to gain insights into the company's financial status and research progress. Participants can access the live conference call by registering in advance, with an audio webcast available on the company's investor relations website.
